Easton Pharmaceuticals (EAPH) Ratios
Easton Pharmaceuticals Ratios
EAPH's free cash flow for Q3 2021 was $-78.15K. For the 2021 fiscal year, EAPH's free cash flow was decreased by $-18.80K and operating cash flow was $-59.35K. See a summary of the company’s cash flow.
| Ratios | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|
| Liquidity Ratios | |||
| Current Ratio | 0.69 | 0.17 | 0.08 |
| Quick Ratio | 0.69 | 0.17 | 0.08 |
| Cash Ratio | 37355.03 | 0.17 | 0.08 |
| Solvency Ratio | -0.00 | -0.00 | -0.02 |
| Operating Cash Flow Ratio | -0.30 | 0.35 | -0.01 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -2.86M | $ -9.83M | $ -2.95M |
| Leverage Ratios | |||
| Debt-to-Assets Ratio | 0.24 | 0.49 | 0.21 |
| Debt-to-Equity Ratio | 0.36 | 1.19 | 0.30 |
| Debt-to-Capital Ratio | 0.26 | 0.54 | 0.23 |
| Long-Term Debt-to-Capital Ratio | 0.26 | 0.54 | 0.23 |
| Financial Leverage Ratio | 1.48 | 2.42 | 1.42 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 3.08 | 6.29 | 0.21 |
| Interest Debt Per Share | 0.00 | 0.01 | 0.00 |
| Net Debt to EBITDA | 2784284.05 | -1246.41 | -17.01 |
| Profitability Margins | |||
| Gross Profit Margin | 0.00% | 12.94% | 28.24% |
| EBIT Margin | 0.00% | -20.76% | -32.75% |
| EBITDA Margin | 0.00% | -0.42% | -32.75% |
| Operating Profit Margin | 0.00% | -20.69% | -32.75% |
| Pretax Profit Margin | 0.00% | -20.76% | -44.64% |
| Net Profit Margin | 0.00% | -20.76% | -44.64% |
| Continuous Operations Profit Margin | 0.00% | -20.76% | -44.64% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 100.00% | 100.31% | 136.29% |
| Return on Assets (ROA) | -1.85% | -1.88% | -1.67% |
| Return on Equity (ROE) | -2.74% | -4.55% | -2.37% |
| Return on Capital Employed (ROCE) | -1.97% | -2.05% | -1.33% |
| Return on Invested Capital (ROIC) | -1.97% | -2.05% | -1.33% |
| Return on Tangible Assets | -8.40% | -3.60% | -8.63% |
| Earnings Yield | -23.42% | -24.02% | -1.62% |
| Efficiency Ratios | |||
| Receivables Turnover | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 1.60 | 0.48 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.22 | 0.00 |
| Asset Turnover | 0.00 | 0.09 | 0.04 |
| Working Capital Turnover Ratio | 0.00 | -1.61 | -0.98 |
| Cash Conversion Cycle | 0.00 | -227.81 | -763.75 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 227.81 | 763.75 |
| Operating Cycle | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||
| Operating Cash Flow Per Share | -0.00 | 0.00 | -0.00 |
| Free Cash Flow Per Share | -0.00 | 0.00 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | -10.03 | 27.17 | 0.00 |
| Capital Expenditure Coverage Ratio | -10.03 | 27.17 | 0.00 |
| Operating Cash Flow Coverage Ratio | -0.08 | 0.06 | -0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.33 | -0.02 |
| Free Cash Flow Yield | -25.69% | 36.57% | -0.07% |
| Valuation Ratios | |||
| Price-to-Earnings (P/E) Ratio | -4.27 | -4.16 | -61.64 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.86 | 27.52 |
| Price-to-Book (P/B) Ratio | 0.12 | 0.19 | 1.46 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.89 | 2.73 | -1519.54 |
| Price-to-Operating Cash Flow Ratio | -4.28 | 2.63 | -1519.54 |
| Price-to-Earnings Growth (PEG) Ratio | 0.09 | -0.04 | 0.31 |
| Enterprise Value Multiple | 2784187.15 | -1450.56 | -101.03 |
| Enterprise Value | -23.19B | 9.56M | 12.53M |
| EV to EBITDA | 2784187.15 | -1450.56 | -101.03 |
| EV to Sales | 0.00 | 6.14 | 33.09 |
| EV to Free Cash Flow | 111829.95 | 19.43 | -1827.23 |
| EV to Operating Cash Flow | 122979.02 | 18.71 | -1827.23 |
| Tangible Book Value Per Share | -0.00 | -0.00 | -0.00 |
| Shareholders’ Equity Per Share | 0.01 | 0.01 | 0.01 |
| Tax and Other Ratios | |||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.00 | -0.00 | -0.00 |
| Tax Burden | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.36 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.33 | 0.61 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.00 | -1.58 | 0.04 |
Currency in USD
